With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group (the “Group”) will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients. With this, the Group aims to establish itself as a Global Specialized Player by 2033.



Showcase Sumitomo Pharma in a nutshell
Here you can search for the strengths of Sumitomo Pharma’s business, Sumitomo Pharma’s initiatives, and other information that interests you by selecting tags.
-
Presentation Material (Mid-term Business Plan 2027)
-
Message from the President
- Profile
-
About Sumitomo Pharma
- Profile
-
Sumitomo Pharma’s challenge
- Profile
-
Sumitomo Pharma’s DX
- DX
-
Philosophy
- Profile
-
Video / Ad Library
- Profile
-
Official Facebook page
- Profile
-
Official YouTube channel
- Profile
No results were found matching your search.
Strengths Sumitomo Pharma’s Three Strengths
- 1R&D Capabilities
- 2Human Resources
- 3Global Business Platforms
Sumitomo Pharma
Group Companies
Select area to see our subsidiaries information.
- -Japan
- -The United States
- -Asia
China
- Sumitomo Pharma (China) Co., Ltd.
- Sumitomo Pharma (Suzhou) Co., Ltd.
Singapore
- Sumitomo Pharma Asia Pacific Pte. Ltd.
Thailand
Taiwan
- Sumitomo Pharma Taiwan Co., Ltd.
Malaysia
- Sumitomo Pharma Malaysia Sdn. Bhd.
Vietnam
- The Representative Office of Sumitomo Pharma Asia Pacific Pte. Ltd. In Ho Chi Minh City
Sumitomo Pharma Co., Ltd.
Japan
Osaka
- Osaka Head Office
- Central Research Laboratories
- Osaka Research Center
Tokyo
- Tokyo Head Office
Kobe
- Regenerative & Cellular Medicine Kobe Center
News Room
Press Releases
- May 25, 2023 Submission of clinical trial notification for RPE tear using RPE cells derived from allogeneic iPS cells (HLCR011) R&D
- May 23, 2023 Posted Investors Meeting Presentation for FY2022 (Year ended March 31, 2023) [Webcast] Finances
- May 15, 2023 Investors Meeting Presentation for FY2022 (Year ended March 31, 2023)(PDF/672KB) Finances
- May 15, 2023 Supplementary Financial Data (IFRS) for the Year Ended March 31, 2023(PDF/302KB) Finances
- May 15, 2023 Summary of Consolidated Financial Results for the Year Ended March 31, 2023 [IFRS](PDF/261KB) Finances
Notices
- Apr. 26, 2023 Sumitomo Pharma Redesigns Corporate Website Others
- Nov. 30, 2022 Posted Factbook 2022 ver.2 Others
- Sep. 13, 2022 Posted Integrated Report 2022 Others
For the Press
Our latest press releases and other information for members of the press,
including various data sets and guidelines for their use.
-
Sustainability
Sumitomo Pharma defines the practice of its Corporate Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as CSR-based management. To this end , Sumitomo Pharma is pursuing CSR-based management through a variety of initiatives, including the development of innovative products and healthcare solutions, and contribution to the development of science.
-
About Us
Message from the President, corporate profile of Sumitomo Pharma, business activities, mid-term management plan, main offices and subsidiaries, etc.
-
Investor Relations
Information for shareholders and investors of Sumitomo Pharma, including management policies, IR materials, and stock and shareholder-related information.